Division of Endocrinology, Hospital for Special Surgery, New York, NY, United States; Metabolic Bone Service, Hospital for Special Surgery, New York, United States.
Metabolic Bone Service, Hospital for Special Surgery, New York, United States.
J Nutr. 2023 May;153(5):1420-1426. doi: 10.1016/j.tjnut.2023.03.001. Epub 2023 Mar 5.
Recognition of the role of vitamin D in immune function has led to interest in its relationship with SARS-CoV-2 infection. Although clinical studies to date have had conflicting results, many individuals currently take high doses of vitamin D to prevent infection.
The goal of this study was to investigate the relationship between serum 25-hydroxyvitamin D (25OHD) and vitamin D supplement use with incident SARS-CoV-2 infection.
In this prospective cohort study, 250 health care workers were enrolled at a single institution and observed for 15 mo. Participants completed questionnaires every 3 mo regarding new SARS-CoV-2 infection, vaccination, and supplement use. Serum was drawn at baseline, 6, and 12 mo for 25OHD and SARS-CoV-2 nucleocapsid antibodies.
The mean age of the participants was 40 y, BMI 26 kg/m, 71% were Caucasian, and 78% female. Over 15 mo, 56 participants (22%) developed incident SARS-CoV-2 infections. At baseline, ∼50% reported using vitamin D supplements (mean daily dose 2250 units). Mean serum 25OHD was 38 ng/mL. Baseline 25OHD did not predict incident SARS-CoV-2 infection (OR: 0.98; 95% CI: 0.80, 1.20). Neither the use of vitamin D supplements (OR: 1.18; 95% CI: 0.65, 2.14) or supplement dose was associated with incident infection (OR: 1.01 per 100-units increase; 95% CI: 0.99, 1.02).
In this prospective study of health care workers, neither serum 25OHD nor the use of vitamin D supplements was associated with the incident SARS-CoV-2 infection. Our findings argue against the common practice of consuming high-dose vitamin D supplements for the presumed prevention of COVID-19.
人们认识到维生素 D 在免疫功能中的作用,因此关注其与 SARS-CoV-2 感染的关系。尽管迄今为止的临床研究结果相互矛盾,但目前许多人服用大剂量维生素 D 来预防感染。
本研究旨在探讨血清 25-羟维生素 D(25OHD)和维生素 D 补充剂的使用与 SARS-CoV-2 感染之间的关系。
在这项前瞻性队列研究中,在一家机构招募了 250 名医护人员,观察期为 15 个月。参与者每 3 个月完成一次关于新 SARS-CoV-2 感染、疫苗接种和补充剂使用的问卷调查。在基线、6 个月和 12 个月时抽取血清,用于检测 25OHD 和 SARS-CoV-2 核衣壳抗体。
参与者的平均年龄为 40 岁,BMI 为 26kg/m2,71%为白种人,78%为女性。在 15 个月的时间里,有 56 名参与者(22%)发生了 SARS-CoV-2 感染事件。基线时,约 50%的人报告服用维生素 D 补充剂(平均每日剂量 2250 单位)。平均血清 25OHD 为 38ng/ml。基线 25OHD 与 SARS-CoV-2 感染无关(OR:0.98;95%CI:0.80,1.20)。服用维生素 D 补充剂(OR:1.18;95%CI:0.65,2.14)或补充剂剂量与感染事件均无关联(每增加 100 单位,OR:1.01;95%CI:0.99,1.02)。
在这项针对医护人员的前瞻性研究中,血清 25OHD 和维生素 D 补充剂的使用均与 SARS-CoV-2 感染无关。我们的研究结果反对普遍存在的高剂量维生素 D 补充剂用于预防 COVID-19 的做法。